背景:原发性醛固酮增多症(PA)的治疗策略包括单侧肾上腺切除术和盐皮质激素受体(MR)拮抗剂的药物治疗。这两种不同的治疗策略在减轻PA对结果的不利影响方面是否具有可比性仍存在争议。
目的:本系统评价的主要目的是确定,评估和综合现有文献,比较PA患者治疗后的临床结果。
方法:将使用PubMed进行系统和全面的搜索,WebofScience和EMBASE,对于2022年12月之前发表的研究。观察性和介入性研究将有资格纳入。将使用纽卡斯尔-渥太华量表评估观察性研究的质量,而介入研究将使用CochraneEffectivePracticeOrganizationofCare工具进行评估。收集的证据将以叙述方式综合。我们将进行荟萃分析,以汇集被认为是同质的研究的估计。系统评价和荟萃分析的报告将根据系统评价和荟萃分析指南的流行病学首选报告项目的观察性研究的荟萃分析。
背景:由于本研究仅基于已发表的文献,不需要道德批准。这次审查的目的是提供一些关于结果的估计,包括生存,临床和生化控制率,心血管和脑血管事件,以及有关生活质量和肾功能的数据,在接受手术治疗或MR拮抗剂治疗的PA患者中。研究结果将在科学会议上发表,并将发表在国际同行评审的科学杂志上。
■CRD42022362506。
Treatment strategies for primary aldosteronism (PA) include unilateral adrenalectomy and medical treatment with mineralocorticoid receptor (MR) antagonists. Whether these two different treatment strategies are comparable in mitigating the detrimental effect of PA on outcomes is still debated.
The primary aim of this systematic
review is to identify, appraise and synthesise existing literature comparing clinical outcomes after treatment in patients with PA.
A systematic and comprehensive search will be performed using PubMed, Web of Science and EMBASE, for studies published until December 2022. Observational and interventional studies will be eligible for inclusion. The quality of observational studies will be assessed using the Newcastle-Ottawa Scale, while interventional studies will be assessed using the Cochrane Effective Practice Organization of Care tool. The collected evidence will be narratively synthesised. We will perform meta-analysis to pool estimates from studies considered to be homogeneous. Reporting of the systematic
review and meta-analysis will be in accordance with the Meta-analysis of Observational Studies in Epidemiology Preferred Reporting Items for Systematic reviews and Meta-Analysis guidelines.
As this study is based solely on the published literature, no ethics approval is required. This
review will aim to provide some estimates on outcomes, including survival, rates of clinical and biochemical control, cardiovascular and cerebrovascular events, as well as data on quality of life and renal function, in patients with PA treated surgically or with MR antagonists. The study findings will be presented at scientific meetings and will be published in an international peer-reviewed scientific journal.
CRD42022362506.